Tatva Chintan AGM approves all 10 resolutions including director re-appointments
- All 10 resolutions proposed at the 30th AGM were passed with requisite majority
- Re-appointment of MD Chintan Nitinkumar Shah and two WTDs approved for three years
- Borrowing limits increased and charges on assets created under Companies Act provisions
- Audited financial statements for FY26 and dividend declaration approved by shareholders
*this image is generated using AI for illustrative purposes only.
Tatva Chintan Pharma Chem Limited shareholders approved the re-appointment of Chairman and Managing Director Chintan Nitinkumar Shah and Whole-time Directors Shekhar Rasiklal Somani and Ajaykumar Mansukhlal Patel at the 30th Annual General Meeting (AGM) held on September 25, 2026.
The meeting, conducted via Video Conferencing (VC), also ratified the borrowing limits and creation of charges on assets. The resolutions were passed through e-voting, with results to be disseminated by the scrutinizer, M/s. TNT & Associates.
Director re-appointments approved
Shareholders voted to retain the core leadership team for a three-year term effective February 1, 2027. The special business items included:
| Director | Role | Term Start | Resolution Type |
|---|---|---|---|
| Chintan Nitinkumar Shah | Managing Director | February 1, 2027 | Special |
| Ajaykumar Mansukhlal Patel | Whole-time Director | February 1, 2027 | Special |
| Shekhar Rasiklal Somani | Whole-time Director | February 1, 2027 | Special |
Mr. Somani was also re-appointed as a Director retiring by rotation under ordinary business. The remuneration for these roles was fixed as part of the same resolutions.
Financial and operational approvals
The AGM adopted the audited standalone and consolidated financial statements for FY26. Members also approved the declaration of dividend on equity shares for the fiscal year ended March 31, 2026. Specific operational approvals included:
- Increase in borrowing limit under Section 180(1)(c) of the Companies Act, 2013.
- Creation of charges on company assets under Section 180(1)(a).
- Ratification of cost auditor remuneration for FY27.
Meeting proceedings
The meeting commenced at 4:00 pm and concluded at 4:53 pm. A quorum was met with 56 members attending through VC/OAVM. Key managerial personnel present included CFO Ajesh Pillai and Company Secretary Ishwar Nayi. Statutory auditor M/s. NDJ & Co. and secretarial auditor M/s. TNT & Associates were also in attendance. The Board’s report and statutory audit reports were taken as read, with no questions raised during the session.
Historical Stock Returns for Tatva Chintan Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.74% | +4.89% | +11.69% | +54.53% | +66.48% | -18.78% |
How will the newly approved increase in borrowing limits impact Tatva Chintan's capital expenditure plans for FY27?
What specific strategic initiatives are expected to drive growth under the continued leadership of Chintan Nitinkumar Shah over the next three years?
How might the ratification of charges on company assets affect the firm's future debt financing costs and credit ratings?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
